Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
| ▸ | CHKA | P35790 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351185 | 0.87 | ALDH1A1 (0.54) | TRPV6NPC1TP53RAB9AKDM4E | |
| SCHEMBL2490300 | 0.87 | ALDH1A1 (0.54) | TRPV6NPC1TP53RAB9AKDM4E | |
| SCHEMBL3869875 | 0.84 | HRH3 (0.55) | TRPV6NCF1KDM4ECYP11B1ALDH1A1 | |
| SCHEMBL29725200 | 0.84 | HRH3 (0.55) | TRPV6NCF1KDM4ECYP11B1ALDH1A1 | |
| SCHEMBL18823130 | 0.84 | TRPV6 (0.51) | TRPV6LMNAKDM4ECYP11B1ALDH1A1 | |
| SCHEMBL5259068 | 0.84 | TRPV6 (0.51) | TRPV6LMNANPC1TP53RAB9A | |
| SCHEMBL1858355 | 0.83 | HRH3 (0.59) | TRPV6KDM4ECYP11B1ALDH1A1TDP1 | |
| SCHEMBL31093419 | 0.83 | HRH3 (0.59) | TRPV6KDM4ECYP11B1ALDH1A1TDP1 | |
| SCHEMBL21550860 | 0.83 | TRPV6 (0.50) | TRPV6CYP11B1 | |
| SCHEMBL18823134 | 0.83 | HRH3 (0.53) | TRPV6KDM4ECYP11B1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-12258328-B2 | 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2025-03-25 | — | — | US | disclosed |
| WO-2025007863-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-119241532-A | 1H-pyrazolo [4,3-c ] pyridine compound, composition and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4464699-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Lisen Therapeutics, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240360145-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | LISEN THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-106459063-A | MERKs-specific pyrimidine compounds | 北卡罗来纳-查佩尔山大学 | 2017-02-22 | — | — | CN | disclosed |
| EP-3129377-A1 | MERTK-SPECIFIC PYRIMIDINE COMPOUNDS | The University of North Carolina at Chapel Hill (US) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015157115-A1 | MERTK-SPECIFIC PYRIMIDINE COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150291609-A1 | MERTK-SPECIFIC PYRIMIDINE COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2015-10-15 | — | — | US | disclosed |
| US-20150291609-A1 | MERTK-SPECIFIC PYRIMIDINE COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2015-10-15 | — | — | US | disclosed |
| WO-2015157115-A1 | MERTK-SPECIFIC PYRIMIDINE COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150291609-A1 | MERTK-SPECIFIC PYRIMIDINE COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2015-10-15 | — | — | US | disclosed |
| EP-2229377-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | Wyeth LLC (US) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009076602-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-1268431-B1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | TRPV6 778/4885LMNA 3918/4885MC4R 552/4885 |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | TRPV6 778/4885LMNA 3918/4885MC4R 552/4885 |
| US-20240360145-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | DPYD, TYMP, TYMS | TRPV6 3685/4885LMNA 4177/4885MC4R 1275/4885 |
| US-12258328-B2 | 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | TRPV6 1765/4885LMNA 4852/4885MC4R 3418/4885 |
| US-20150291609-A1 | MERTK-SPECIFIC PYRIMIDINE COMPOUNDS | MERTK, TYRO3, MATK | TRPV6 3236/4885LMNA 4681/4885MC4R 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.